Sai Parenterals Ltd
Sai Parenterals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #77 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
3 of 5 strong
The short version
Sai Parenterals targets Rs. FY '27 guidance: Revenue target of Rs.
From Sai Parenterals Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Sai Parenterals targets Rs. 750 crore revenue for FY '27 with 17% EBITDA margin, expecting the year to be weighted towards the second half.
- FY '27 is considered a building year; significant growth anticipated from FY '28 as new assets and acquisitions begin contributing to earnings and cash flows.
- Noumed expansion expects additional order wins, including a large AUD 202 million contract, with new product developments adding incremental revenue beyond existing orders.
- The new EU-GMP injectable facility and R&D acquisition will boost capacity and product offerings, particularly in regulated markets (Europe, ROW).
- US market entry through a newly formed subsidiary is in preliminary evaluation; potential contribution remains under assessment.
2 more points from Sai Parenterals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sai Parenterals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Rs. 83.83 crores invested for a 60% equity stake in Saicriti Pharma Pvt Ltd to build a critical care injectable facility at Gummadidala, Hyderabad (EU GMP and USFDA standards).
- Total project cost of Rs. 217 crores; balance 40% funded by Saicriti promoters and additional project debt.
- Acquisition of 60% equity in Prathyak Laboratories for Rs. 15 crores to gain an operational R&D center with 150 SKUs across 86 molecules, accelerating product development.
- AUD 5 million funding to complete Australian facility; AUD 3.5 million contributed via Singapore subsidiary.
- Proposal to establish a US subsidiary via Singapore for market entry (currently under evaluation).
2 more points from Sai Parenterals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sai Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Noumed Pharmaceuticals has secured a significant order from a pharmacy chain in Australia valued at AUD 202 million for the next 12 months.
- This order includes existing products and excludes 12 newer drugs under development, which are expected to add to future order values.
- Noumed anticipates ongoing yearly order wins of similar scale, supported by a standard year-on-year growth of 5%-8% in pharmacy network expansion.
2 more points from Sai Parenterals Ltd's call on order book
Create a free account to keep reading this call
Sai Parenterals Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹198 Cr, net profit ₹13 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sai Parenterals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharmaceuticals Ltd (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sai Parenterals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sai Parenterals Ltd Q1 FY27 results?
Sai Parenterals targets Rs. FY '27 guidance: Revenue target of Rs.
What is Sai Parenterals Ltd share price analysis?
Sai Parenterals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 115.1 with a market cap of ₹2,389 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sai Parenterals Ltd planning capital expenditure?
Rs.
Keep Sai Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.